Drug Type Recombinant LBP |
Synonyms |
Target |
Action inhibitors |
Mechanism KLK5 inhibitors(kallikrein related peptidase 5 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Netherton Syndrome | Preclinical | United States | 23 Oct 2024 |